Fulvestrant for the treatment of locally advanced or metastatic breast cancer

TA239 Breast cancer (metastatic) - fulvestrant: review decision November 2014 information

TA239 Breast cancer (metastatic) - fulvestrant: Appendix A - GE decision paper - November 2014 (PDF 103 KB)

TA239 Breast cancer (metastatic) - fulvestrant: review proposal - August 2014 information

TA239 Breast cancer (metastatic) - fulvestrant: appendix A - matrix of stakeholders (PDF 99 KB)

TA239 Breast cancer (metastatic) - fulvestrant: appendix B - proposal paper presented to the Institute's Guidance Executive (PDF 267 KB)

Breast cancer (metastatic) - fulvestrant: Equality Impact Assessment (PDF 76 KB)

Breast cancer (metastatic) - fulvestrant: final appraisal determination information

Breast cancer (metastatic) - fulvestrant: final appraisal determination document (PDF 307 KB)

Breast cancer (metastatic) - fulvestrant: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 311 KB)

Breast cancer (metastatic) - fulvestrant: consultee and commentator comments on the ACD

Breast cancer (metastatic) - fulvestrant: AstraZeneca (PDF 669 KB)

Breast cancer (metastatic) - fulvestrant: Breakthrough Breast Cancer (PDF 35 KB)

Breast cancer (metastatic) - fulvestrant: Royal College of Nursing (PDF 57 KB)

Breast cancer (metastatic) - fulvestrant: joint comment from National Cancer Research Institute, Royal College of Physician, Royal College of Radiologists, Association of Cancer Physicians and Joint Collegiate Council for Oncology (PDF 145 KB)

Breast cancer (metastatic) - fulvestrant: South Staffordshire PCT (PDF 8.2 KB)

Breast cancer (metastatic) - fulvestrant: Commissioning Support Appraisals Service (PDF 264 KB)

Breast cancer (metastatic) - fulvestrant: comments on the ACD received from the public through the NICE website (PDF 70 KB)

Breast cancer (metastatic) - fulvestrant: appraisal consultation

Breast cancer (metastatic) - fulvestrant: appraisal consultation document information

Breast cancer (metastatic) - fulvestrant: evaluation report

Breast cancer (metastatic) - fulvestrant: pre-meeting briefing (PDF 137 KB)

Breast cancer (metastatic) - fulvestrant: Evidence Review Group report (PDF 1.77 MB)

Breast cancer (metastatic) - fulvestrant: Evidence Review Group report - addendum (PDF 102 KB)

Breast cancer (metastatic) - fulvestrant: Evidence Review Group report - factual accuracy check (PDF 180 KB)

Breast cancer (metastatic) - fulvestrant: manufacturer submission

Breast cancer (metastatic) - fulvestrant: manufacturer submission from AstraZeneca (PDF 4.78 MB)

Breast cancer (metastatic) - fulvestrant: NICE clarification letter (PDF 77 KB)

Breast cancer (metastatic) - fulvestrant: manufacturer response to the NICE clarification letter (PDF 418 KB)

Breast cancer (metastatic) - fulvestrant: request for further clarification (PDF 142 KB)

Breast cancer (metastatic) - fulvestrant: manufacturer response to further clarification request (PDF 4.7 KB)

Breast cancer (metastatic) - fulvestrant: patient group, professional group and NHS organisation submission statements

Breast cancer (metastatic) - fulvestrant: joint submission from Breast Cancer Care, Breakthrough Breast Cancer, Macmillan Cancer Support and Breast Cancer Campaign (PDF 78 KB)

Breast cancer (metastatic) - fulvestrant: submission from Royal College of Pathologists (PDF 78 KB)

Breast cancer (metastatic) - fulvestrant: joint submission from NCRI/RCP/RCR/ACP/JCCO (PDF 100 KB)

Breast cancer (metastatic) - fulvestrant: expert statement from Hecht (PDF 80 KB)

Breast cancer (metastatic) - fulvestrant: response to consultee and commentator comments on provisional matrix (PDF 17 KB)

Breast cancer (metastatic) - fulvestrant: consultation comments table (PDF 69 KB)

Breast cancer (metastatic) - fulvestrant: final matrix (PDF 32 KB)

Breast cancer (metastatic) - fulvestrant: final scope (PDF 29 KB)

Breast cancer (metastatic) - fulvestrant: provisional matrix (pre-referral) - November 2009 (PDF 43 KB)

Breast cancer (metastatic) - fulvestrant: draft scope for consultation (pre-referral) - November 2009 (PDF 46 KB)